Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability After a Single Dose of Risankizumab

NCT05305222 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05305222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05305222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability After a Single Dose of Risankizumab
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2017
Completion date
June 15, 2018
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers